Cost–benefit analysis for synthetic nucleic acid screening in the European Union
An EU cost–benefit analysis of synthetic DNA/RNA screening policies comparing voluntary, conditional and mandatory approaches. Covers biosecurity risk reduction, market impacts, research effects and regulatory design implications for EU policymakers.
